<DOC>
	<DOCNO>NCT01149252</DOCNO>
	<brief_summary>The purpose study determine safety efficacy new product , Psoralait , compare placebo treatment psoriasis .</brief_summary>
	<brief_title>Determination Efficacy Safety Psoralait Versus Placebo Treatment Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Patients clinically diagnose suffer psoriasis n't schedule Narrow Band Ultraviolet B ( UVB ) phototherapy affect area , exclude face genitalia . Women pregnant , lactating , plan become pregnant , woman childbearing potential successfully use medically acceptable contraceptive method previous 3 month , e.g. , oral contraceptive agent , intrauterine device ( IUD ) barrier method plus spermicide . Use topical anti psoriatic therapy ( include topical retinoids , corticosteroid , vitamin D analog ) area treat within 2 week prior begin study . Received systemic biologic therapy treat psoriasis ( example : alefacept , etanercept , infliximab , adalimumab ) within 12 week prior begin study . Received systemic psoriasis therapy ( example : methotrexate , cyclosporine , systemic corticosteroid , retinoids acitretin ) within 4 week prior begin study . Received phototherapy ( include laser ) , photo chemotherapy climatotherapy within 4 week prior begin study . Recent history ( within past 12 month ) alcohol substance abuse . Alcohol abuse define &gt; 14 drink per week ( 1 drink = 12 oz beer , 4 oz wine , 1.5 oz distil spirit ) . History noncompliance medical regimen unwilling comply study protocol . Participation investigational drug study within 30 day prior begin study . Serious unstable medical psychological condition opinion Investigator would compromise subject 's safety successful participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>